Position
BRAIDWELL LP in Nurix Therapeutics, Inc.
Back to the book · All holders of NRIX
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$6.08M$18.97 → $15.50
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 2.18M | $41.4M | — | — | — | 1.3% |
| Q1 2026 | 1.75M | $27.1M | $15.50 | −$6.08M | −$8.22M | 0.9% |